Axel Grothey

1998–2025 年に発表

168
論文数
43,559
被引用数
95
h 指数
165
i10 指数

被引用数

Axel Grothey の年別被引用数1991 年: 被引用 2 件1993 年: 被引用 1 件1995 年: 被引用 2 件1999 年: 被引用 1 件2000 年: 被引用 4 件2001 年: 被引用 5 件2002 年: 被引用 30 件2003 年: 被引用 38 件2004 年: 被引用 39 件2005 年: 被引用 64 件2006 年: 被引用 67 件2007 年: 被引用 122 件2008 年: 被引用 115 件2009 年: 被引用 160 件2010 年: 被引用 210 件2011 年: 被引用 218 件2012 年: 被引用 199 件2013 年: 被引用 211 件2014 年: 被引用 228 件2015 年: 被引用 266 件2016 年: 被引用 219 件2017 年: 被引用 315 件2018 年: 被引用 287 件2019 年: 被引用 1,401 件2020 年: 被引用 1,862 件2021 年: 被引用 1,851 件2022 年: 被引用 1,335 件2023 年: 被引用 980 件2024 年: 被引用 1,659 件2025 年: 被引用 661 件2026 年: 被引用 15 件1992 年は被引用が無いため表示していません1994 年は被引用が無いため表示していません1996〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,294 件、この内訳の 20.4%中国: 引用元論文 2,036 件、この内訳の 12.6%イタリア: 引用元論文 1,222 件、この内訳の 7.6%イギリス: 引用元論文 871 件、この内訳の 5.4%フランス: 引用元論文 812 件、この内訳の 5%ドイツ: 引用元論文 746 件、この内訳の 4.6%日本: 引用元論文 708 件、この内訳の 4.4%スペイン: 引用元論文 615 件、この内訳の 3.8%オランダ: 引用元論文 538 件、この内訳の 3.3%カナダ: 引用元論文 452 件、この内訳の 2.8%オーストラリア: 引用元論文 427 件、この内訳の 2.7%韓国: 引用元論文 370 件、この内訳の 2.3%
0%20.4%その他 25.1%

分野

  • Medicine75.4%
  • Biochemistry, Genetics and Molecular Biology17.9%
  • Immunology and Microbiology1.4%
  • Mathematics0.7%
  • Computer Science0.7%
  • Engineering0.7%
  • その他3.2%

トピック

  • Colorectal Cancer Treatments and Studies10%
  • Colorectal Cancer Surgical Treatments4.5%
  • Genetic factors in colorectal cancer4.4%
  • Cancer Immunotherapy and Biomarkers4%
  • Cancer Genomics and Diagnostics3.7%
  • Hepatocellular Carcinoma Treatment and Prognosis3.3%
  • その他70.1%

共著者

全論文

検索で開く
  1. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero - New England Journal of Medicine 2019 被引用: 1,465

  2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2012 被引用: 2,897

  3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 被引用: 3,449

  4. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

    著者: , , , , , , , , , , , , , , , , , , - JAMA Oncology 2019 被引用: 846

  5. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 544

  6. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 413

  7. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,126

  8. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 被引用: 161

  9. Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 1,613

  10. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 660

  11. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 955

  12. 5-fluorouracil and cardiotoxicity: a review

    著者: , , , , , , , , - Therapeutic Advances in Medical Oncology 2018 被引用: 421

  13. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2018 被引用: 994

  14. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

    著者: , , - Annals of Oncology 2021 被引用: 211

  15. NCCN Guidelines Insights: Colon Cancer, Version 2.2018

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elena M. Stoffel, Eden Stotsky‐Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2018 被引用: 1,029

  16. Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 676

  17. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 592

  18. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 298

  19. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 172

  20. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

    著者: , , , , , , , , , , , , , - Annals of Surgery 2019 被引用: 437

  21. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - JAMA 2021 被引用: 130

  22. Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

    著者: , , , , , , , , , , , , , , - JCO Precision Oncology 2022 被引用: 95

  23. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 被引用: 66

  24. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2021 被引用: 182